Holders — by stockHoldings — by fund
TCG Crossover Management, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001839948
$3.54B
disclosed book value
57
positions
10.2%
largest position share
Positions, as of 2026-09-30
top 57 of 57 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ABVXABIVAX SA AMERICAN DEPOSITARY SHARES | 3.7M | $362.7M | 10.2% |
| 2 | CGONCG ONCOLOGY INC | 3.7M | $260.2M | 7.4% |
| 3 | AMLXAMYLYX PHARMACEUTICALS INC | 6.2M | $181.7M | 5.1% |
| 4 | SYRESPYRE THERAPEUTICS INC | 1.9M | $169.2M | 4.8% |
| 5 | TNGXTANGO THERAPEUTICS INC | 6.8M | $169.0M | 4.8% |
| 6 | ZLABZAI LAB LTD-ADR | 6.2M | $164.1M | 4.6% |
| 7 | IMVTIMMUNOVANT INC | 4.5M | $150.6M | 4.3% |
| 8 | DNTHDIANTHUS THERAPEUTICS INC | 1.7M | $147.6M | 4.2% |
| 9 | KRSAKORSANA BIOSCIENCES INC | 4.5M | $145.6M | 4.1% |
| 10 | KODKODIAK SCIENCES INC | 1.4M | $137.0M | 3.9% |
| 11 | VORVOR BIOPHARMA INC | 5.7M | $108.2M | 3.1% |
| 12 | TRAXFIRST TRACKS BIOTHERAPEUTICS | 2.9M | $102.6M | 2.9% |
| 13 | MIRMMIRUM PHARMACEUTICALS INC | 1.1M | $95.6M | 2.7% |
| 14 | BCRXBIOCRYST PHARMACEUTICALS INC | 11.0M | $91.8M | 2.6% |
| 15 | IRONDISC MEDICINE INC | 1.3M | $87.8M | 2.5% |
| 16 | ADRXADARX PHARMACEUTICALS INC | 4.1M | $82.1M | 2.3% |
| 17 | COGTCOGENT BIOSCIENCES INC | 2.5M | $80.1M | 2.3% |
| 18 | TYRATYRA BIOSCIENCES INC | 3.5M | $76.0M | 2.1% |
| 19 | DYNDYNE THERAPEUTICS INC | 4.6M | $74.3M | 2.1% |
| 20 | RLAYRELAY THERAPEUTICS INC | 3.8M | $68.3M | 1.9% |
| 21 | AURAAURA BIOSCIENCES INC | 10.2M | $63.8M | 1.8% |
| 22 | SVRASAVARA INC | 12.4M | $63.8M | 1.8% |
| 23 | XNCRXENCOR INC | 2.1M | $51.3M | 1.4% |
| 24 | AVTXAVALO THERAPEUTICS INC | 3.0M | $46.3M | 1.3% |
| 25 | GLUEMONTE ROSA THERAPEUTICS INC | 3.8M | $45.1M | 1.3% |
| 26 | MBXMBX BIOSCIENCES INC | 650,000 | $38.1M | 1.1% |
| 27 | ENTXENTERA BIO LTD | 12.3M | $35.7M | 1% |
| 28 | JANXJANUX THERAPEUTICS INC | 1.8M | $30.9M | 0.9% |
| 29 | TARSTARSUS PHARMACEUTICALS INC | 388,164 | $30.5M | 0.9% |
| 30 | IPSCCENTURY THERAPEUTICS INC | 17.8M | $30.4M | 0.9% |
| 31 | OBXOBSIDIAN THERAPEUTICS INC | 2.2M | $30.2M | 0.9% |
| 32 | PHVSPHARVARIS BV | 947,544 | $30.1M | 0.8% |
| 33 | LBRXLB PHARMACEUTICALS INC | 765,050 | $29.4M | 0.8% |
| 34 | EDITEDITAS MEDICINE INC | 11.1M | $28.6M | 0.8% |
| 35 | TECXTECTONIC THERAPEUTIC INC | 1.2M | $28.1M | 0.8% |
| 36 | IFRXINFLARX N V | 14.5M | $26.1M | 0.7% |
| 37 | CATXPERSPECTIVE THERAPEUTICS INC | 7.9M | $21.8M | 0.6% |
| 38 | AGMBAGOMAB THERAPEUTICS NV | 1.8M | $20.2M | 0.6% |
| 39 | SLNSILENCE THERAPEUTICS PLC | 1.8M | $19.9M | 0.6% |
| 40 | ALECALECTOR INC | 10.0M | $18.5M | 0.5% |
| 41 | BHVNBIOHAVEN LTD | 1.3M | $16.9M | 0.5% |
| 42 | MNPRMONOPAR THERAPEUTICS INC | 202,242 | $16.1M | 0.5% |
| 43 | ADCTADC THERAPEUTICS SA | 11.4M | $13.9M | 0.4% |
| 44 | TRDAENTRADA THERAPEUTICS INC | 1.1M | $6.7M | 0.2% |
| 45 | CGEMCULLINAN THERAPEUTICS INC | 406,786 | $6.2M | 0.2% |
| 46 | AGENAGENUS INC | 603,892 | $6.0M | 0.2% |
| 47 | OCULOCULAR THERAPEUTIX INC | 720,323 | $5.5M | 0.2% |
| 48 | ARVNARVINAS INC | 707,098 | $5.5M | 0.2% |
| 49 | KRROKORRO BIO INC | 416,301 | $4.1M | 0.1% |
| 50 | RACDRESEARCH ALLIANCE CORP IV-A | 300,000 | $3.6M | 0.1% |
| 51 | ALXOALX ONCOLOGY HOLDINGS INC | 2.5M | $3.4M | 0.1% |
| 52 | AKTSAKTIS ONCOLOGY INC | 133,457 | $2.6M | 0.1% |
| 53 | JATTJATT II ACQUISITION CORP | 200,000 | $2.2M | 0.1% |
| 54 | LONALEONABIO INC | 464,398 | $1.7M | 0% |
| 55 | JTTTJATT III ACQUISITION CORP | 100,000 | $1.1M | 0% |
| 56 | CNTXCONTEXT THERAPEUTICS INC | 2.7M | $805,882 | 0% |
| 57 | EIKNEIKON THERAPEUTICS INC | 37,902 | $304,732 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.